1. Home
  2. RDY vs NABL Comparison

RDY vs NABL Comparison

Compare RDY & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDY
  • NABL
  • Stock Information
  • Founded
  • RDY 1984
  • NABL 2000
  • Country
  • RDY India
  • NABL United States
  • Employees
  • RDY N/A
  • NABL N/A
  • Industry
  • RDY Biotechnology: Pharmaceutical Preparations
  • NABL Computer Software: Prepackaged Software
  • Sector
  • RDY Health Care
  • NABL Technology
  • Exchange
  • RDY Nasdaq
  • NABL Nasdaq
  • Market Cap
  • RDY 2.1B
  • NABL 1.9B
  • IPO Year
  • RDY N/A
  • NABL N/A
  • Fundamental
  • Price
  • RDY $13.17
  • NABL $7.19
  • Analyst Decision
  • RDY Buy
  • NABL Buy
  • Analyst Count
  • RDY 1
  • NABL 4
  • Target Price
  • RDY $17.00
  • NABL $9.38
  • AVG Volume (30 Days)
  • RDY 1.9M
  • NABL 1.2M
  • Earning Date
  • RDY 05-06-2025
  • NABL 03-03-2025
  • Dividend Yield
  • RDY 3.63%
  • NABL N/A
  • EPS Growth
  • RDY 2.68
  • NABL 24.64
  • EPS
  • RDY 0.75
  • NABL 0.16
  • Revenue
  • RDY $3,637,607,642.00
  • NABL $466,147,000.00
  • Revenue This Year
  • RDY $17.23
  • NABL $8.45
  • Revenue Next Year
  • RDY $9.19
  • NABL $9.68
  • P/E Ratio
  • RDY $17.92
  • NABL $44.91
  • Revenue Growth
  • RDY 14.74
  • NABL 10.49
  • 52 Week Low
  • RDY $12.50
  • NABL $6.75
  • 52 Week High
  • RDY $16.89
  • NABL $15.49
  • Technical
  • Relative Strength Index (RSI)
  • RDY 45.70
  • NABL 35.52
  • Support Level
  • RDY $13.10
  • NABL $7.04
  • Resistance Level
  • RDY $13.85
  • NABL $7.38
  • Average True Range (ATR)
  • RDY 0.13
  • NABL 0.27
  • MACD
  • RDY 0.03
  • NABL 0.04
  • Stochastic Oscillator
  • RDY 48.88
  • NABL 16.04

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. it also has a presence in the United Kingdom and all other International regions.

Share on Social Networks: